AIkido Pharma Files Patent Application for the Use of Ketamine
23 Jun 2021 //
PRNEWSWIRE
AIkido Pharma Notes Advancement in Radiopharmaceutical Research
16 Apr 2021 //
PRNEWSWIRE
AIkido Granted Sublicense to Technology for Targeted Psilocybin
07 Apr 2021 //
PRNEWSWIRE
AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD
29 Mar 2021 //
PRNEWSWIRE
AIkido Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
01 Mar 2021 //
PRNEWSWIRE
AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus
22 Feb 2021 //
PRNEWSWIRE
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma
16 Feb 2021 //
PRNEWSWIRE
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
22 Jan 2021 //
PRNEWSWIRE
AIkido Pharma . Executes Licensing Agreement for Psilocybin
06 Jan 2021 //
PRNEWSWIRE
AIkido Provides Update Its Next-Generation Chemotherapeutic Treatment DHA-dFdC
28 Oct 2020 //
PRNEWSWIRE